The effect of desolvation on the binding of inhibitors to HIV-1 protease and cyclin-dependent kinases: Causes of resistance

被引:8
|
作者
Fong, Clifford W. [1 ]
机构
[1] Eigenenergy, Adelaide, SA, Australia
关键词
QSAR model; HIV-1 protease inhibitors; CDK inhibitors; Kinase binding; Quantum mechanics; RECOGNITION; ENTHALPY; ENERGY; MODELS;
D O I
10.1016/j.bmcl.2016.05.080
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Studies of the cyclin-dependent kinase inhibitors and HIV-1 protease inhibitors have confirmed that ligand-protein binding is dependent on desolvation effects. It has been found that a four parameter linear model incorporating desolvation energy, lipophilicity, dipole moment and molecular volume of the ligands is a good model to describe the binding between ligands and kinases or proteases. The resistance shown by MDR proteases to the anti-viral drugs is multi-faceted involving varying changes in desolvation, lipophilicity and dipole moment interaction compared to the non-resistant protease. Desolvation has been shown to be the dominant factor influencing the effect of inhibitors against the cyclin-dependent kinases, but lipophilicity and dipole moment are also significant factors. The model can differentiate between the inhibitory activity of CDK2/cycE, CDK1/cycB and CDK4/cycD enzymes. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3705 / 3713
页数:9
相关论文
共 50 条
  • [21] Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans
    Fiano, V
    Ghimenti, C
    Schiffer, D
    NEUROSCIENCE LETTERS, 2003, 347 (02) : 111 - 115
  • [22] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
    Alice Grison
    Suzana Atanasoski
    Molecular Neurobiology, 2020, 57 : 3206 - 3218
  • [23] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
    Grison, Alice
    Atanasoski, Suzana
    MOLECULAR NEUROBIOLOGY, 2020, 57 (07) : 3206 - 3218
  • [24] Resistance to HIV-1 protease inhibitors
    Swanstrom, R
    Smith, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 58 - BIOT
  • [25] Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting "block and lock" treatment strategies
    Horvath, Riley M.
    Brumme, Zabrina L.
    Sadowski, Ivan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (03)
  • [26] Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer
    Jeannon, JP
    Wilson, JA
    CLINICAL OTOLARYNGOLOGY, 1998, 23 (05): : 420 - 424
  • [27] Characterization of indenopyrazoles as inhibitors of cyclin-dependent kinases.
    Seitz, SP
    Benfield, PA
    Boylan, J
    Boisclair, M
    Brizuela, L
    Burton, CR
    Carini, DJ
    Chang, CH
    Cox, S
    Czerniak, PM
    Grafstrom, RH
    Hoess, RH
    Muckelbauer, JK
    Nugiel, DA
    Rossi, KA
    Trainor, GL
    Worland, P
    Yue, EW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U1022 - U1022
  • [28] Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors
    Malumbres, M
    Ortega, S
    Barbacid, M
    BIOLOGICAL CHEMISTRY, 2000, 381 (9-10) : 827 - 838
  • [29] Inhibitors of cyclin-dependent Kinases Usage in the Tumor Therapy
    Salmen, J.
    ONKOLOGE, 2016, 22 (03): : 214 - 215
  • [30] Discovery of potent and selective inhibitors of cyclin-dependent kinases
    Keertikar, Kerry M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242